The hypoprothrombinemia treatment market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.52 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth during the historic period can be attributed to the increasing prevalence of liver diseases, a rising incidence of malabsorption syndromes, heightened attention to coagulation disorders in critical care, greater awareness of bleeding disorders, and a surge in vitamin K deficiency cases.
The hypoprothrombinemia treatment market size is expected to see strong growth in the next few years. It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth projected for the forecast period can be attributed to the increasing prevalence of bleeding disorders, rising demand for home care treatments, expansion of healthcare infrastructure, growth in specialty clinics and hematology-focused care centers, and the increasing adoption of personalized medicine. Key trends during this period include advancements in recombinant coagulation factors, personalized medicine and genetic profiling, innovative drug delivery systems, point-of-care diagnostic technologies, as well as the integration of artificial intelligence (AI) and data analytics.
The rising prevalence of bleeding disorders is expected to drive growth in the hypoprothrombinemia treatment market. Bleeding disorders are conditions where blood does not clot properly, causing excessive or prolonged bleeding. This increase in prevalence is largely due to improved diagnostic methods and greater awareness, leading to more accurate identification and reporting of such conditions. Hypoprothrombinemia treatments help restore clotting ability in patients by replenishing deficient prothrombin levels. For example, between April 2022 and March 2023 in the United Kingdom, a total of 6,662 males were diagnosed with hemophilia A, with 5,032 adults (aged 18 and above), and 2,421 of these patients received treatment through either factor replacement therapy or emicizumab, according to BMC Health Services Research, a UK-based journal. During the same period, 1,342 males were recorded with hemophilia B, including 1,022 adults, of whom 479 underwent factor replacement treatment. Therefore, the growing prevalence of bleeding disorders is anticipated to fuel the expansion of the hypoprothrombinemia treatment market.
The increasing adoption of biosimilars is expected to propel growth in the hypoprothrombinemia treatment market moving forward. Biosimilars are biologic medical products that are highly similar to an already approved original biologic, with no significant differences in safety or effectiveness. Their rising use is fueled by the potential to offer more affordable and accessible treatment options while maintaining comparable safety and efficacy to original biologics. In hypoprothrombinemia treatment, biosimilars provide cost-effective alternatives to original clotting factor therapies, enhancing patient access to vital coagulation management. For example, according to PhRMA, a US-based trade association representing leading innovative biopharmaceutical companies, by the end of 2022, 40 biosimilars had received approval, with 27 of them available in the United States. Thus, the growing use of biosimilars is driving the expansion of the hypoprothrombinemia treatment market.
Leading companies in the hypoprothrombinemia treatment market are concentrating on innovative therapies like non-activated four-factor prothrombin complex concentrate (4F-PCC) to quickly restore clotting factor levels and minimize bleeding risks in patients needing urgent anticoagulation reversal. The non-activated 4F-PCC is a plasma-derived treatment that includes clotting factors II, VII, IX, and X, used to promptly counteract the effects of vitamin K antagonists and manage bleeding disorders such as hypoprothrombinemia. For example, in January 2024, Octapharma USA, a subsidiary of Octapharma AG based in the US, launched Balfaxar, a non-activated 4F-PCC recently approved by the FDA for urgent reversal of vitamin K antagonist-induced coagulation deficiencies in adults undergoing emergency surgery or invasive procedures. This therapy contains essential vitamin K-dependent clotting factors along with antithrombotic proteins, fulfilling critical needs in hypoprothrombinemia treatment.
Major players in the hypoprothrombinemia treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc, Sanofi S.A., AstraZeneca, Abbott, GlaxoSmithKline, Takeda Pharmaceuticals, Novo Nordisk A/S, Teva Pharmaceuticals, CSL Limited, Baxter International Inc., Fresenius Kabi AG, Grifols S.A., Sun Pharmaceutical Industries Ltd., Octapharma AG, Dr. Reddy's Laboratories, Pharmascience Inc., Amphastar Pharmaceuticals Inc., Pharma Cure Laboratories.
North America was the largest region in the hypoprothrombinemia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hypoprothrombinemia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the hypoprothrombinemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Hypoprothrombinemia treatment involves medical approaches designed to restore sufficient levels of prothrombin (Factor II), a crucial protein in blood clotting. The goal is to prevent or manage abnormal bleeding by addressing the underlying cause, which may include genetic factors, vitamin K deficiency, liver disease, or excessive use of anticoagulants.
The primary treatment types for hypoprothrombinemia are Type I and Type II deficiency treatments. Type I hypoprothrombinemia (true prothrombin deficiency) is commonly managed with prothrombin complex concentrates (PCCs) or fresh frozen plasma (FFP) to replenish prothrombin levels and enhance clotting function. Treatment options include vitamin K, fresh frozen plasma, prothrombin complex concentrates, and recombinant prothrombin. These therapies are used for conditions such as vitamin K deficiency, liver diseases like cirrhosis and hepatitis, anticoagulant-related hypoprothrombinemia, genetic disorders, and malabsorption syndromes. Drug administration routes include oral, injectable, intravenous, intramuscular, and transfusion-based methods. The main end users are hospitals, specialty clinics, and homecare providers.
The hypoprothrombinemia treatment market research report is one of a series of new reports that provides hypoprothrombinemia treatment market statistics, including the hypoprothrombinemia treatment industry global market size, regional shares, competitors with the hypoprothrombinemia treatment market share, detailed hypoprothrombinemia treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the hypoprothrombinemia treatment industry. This hypoprothrombinemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The hypoprothrombinemia treatment market consists of revenues earned by entities by providing services such as diagnostic testing, hospital care, specialized transfusion services, therapeutic drug monitoring, and patient management programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypoprothrombinemia treatment market also includes sales of plasma-derived concentrates, synthetic clotting factors, oral anticoagulant reversal agents, blood products, and plasma derivatives. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The hypoprothrombinemia treatment market size is expected to see strong growth in the next few years. It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth projected for the forecast period can be attributed to the increasing prevalence of bleeding disorders, rising demand for home care treatments, expansion of healthcare infrastructure, growth in specialty clinics and hematology-focused care centers, and the increasing adoption of personalized medicine. Key trends during this period include advancements in recombinant coagulation factors, personalized medicine and genetic profiling, innovative drug delivery systems, point-of-care diagnostic technologies, as well as the integration of artificial intelligence (AI) and data analytics.
The rising prevalence of bleeding disorders is expected to drive growth in the hypoprothrombinemia treatment market. Bleeding disorders are conditions where blood does not clot properly, causing excessive or prolonged bleeding. This increase in prevalence is largely due to improved diagnostic methods and greater awareness, leading to more accurate identification and reporting of such conditions. Hypoprothrombinemia treatments help restore clotting ability in patients by replenishing deficient prothrombin levels. For example, between April 2022 and March 2023 in the United Kingdom, a total of 6,662 males were diagnosed with hemophilia A, with 5,032 adults (aged 18 and above), and 2,421 of these patients received treatment through either factor replacement therapy or emicizumab, according to BMC Health Services Research, a UK-based journal. During the same period, 1,342 males were recorded with hemophilia B, including 1,022 adults, of whom 479 underwent factor replacement treatment. Therefore, the growing prevalence of bleeding disorders is anticipated to fuel the expansion of the hypoprothrombinemia treatment market.
The increasing adoption of biosimilars is expected to propel growth in the hypoprothrombinemia treatment market moving forward. Biosimilars are biologic medical products that are highly similar to an already approved original biologic, with no significant differences in safety or effectiveness. Their rising use is fueled by the potential to offer more affordable and accessible treatment options while maintaining comparable safety and efficacy to original biologics. In hypoprothrombinemia treatment, biosimilars provide cost-effective alternatives to original clotting factor therapies, enhancing patient access to vital coagulation management. For example, according to PhRMA, a US-based trade association representing leading innovative biopharmaceutical companies, by the end of 2022, 40 biosimilars had received approval, with 27 of them available in the United States. Thus, the growing use of biosimilars is driving the expansion of the hypoprothrombinemia treatment market.
Leading companies in the hypoprothrombinemia treatment market are concentrating on innovative therapies like non-activated four-factor prothrombin complex concentrate (4F-PCC) to quickly restore clotting factor levels and minimize bleeding risks in patients needing urgent anticoagulation reversal. The non-activated 4F-PCC is a plasma-derived treatment that includes clotting factors II, VII, IX, and X, used to promptly counteract the effects of vitamin K antagonists and manage bleeding disorders such as hypoprothrombinemia. For example, in January 2024, Octapharma USA, a subsidiary of Octapharma AG based in the US, launched Balfaxar, a non-activated 4F-PCC recently approved by the FDA for urgent reversal of vitamin K antagonist-induced coagulation deficiencies in adults undergoing emergency surgery or invasive procedures. This therapy contains essential vitamin K-dependent clotting factors along with antithrombotic proteins, fulfilling critical needs in hypoprothrombinemia treatment.
Major players in the hypoprothrombinemia treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc, Sanofi S.A., AstraZeneca, Abbott, GlaxoSmithKline, Takeda Pharmaceuticals, Novo Nordisk A/S, Teva Pharmaceuticals, CSL Limited, Baxter International Inc., Fresenius Kabi AG, Grifols S.A., Sun Pharmaceutical Industries Ltd., Octapharma AG, Dr. Reddy's Laboratories, Pharmascience Inc., Amphastar Pharmaceuticals Inc., Pharma Cure Laboratories.
North America was the largest region in the hypoprothrombinemia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hypoprothrombinemia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the hypoprothrombinemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Hypoprothrombinemia treatment involves medical approaches designed to restore sufficient levels of prothrombin (Factor II), a crucial protein in blood clotting. The goal is to prevent or manage abnormal bleeding by addressing the underlying cause, which may include genetic factors, vitamin K deficiency, liver disease, or excessive use of anticoagulants.
The primary treatment types for hypoprothrombinemia are Type I and Type II deficiency treatments. Type I hypoprothrombinemia (true prothrombin deficiency) is commonly managed with prothrombin complex concentrates (PCCs) or fresh frozen plasma (FFP) to replenish prothrombin levels and enhance clotting function. Treatment options include vitamin K, fresh frozen plasma, prothrombin complex concentrates, and recombinant prothrombin. These therapies are used for conditions such as vitamin K deficiency, liver diseases like cirrhosis and hepatitis, anticoagulant-related hypoprothrombinemia, genetic disorders, and malabsorption syndromes. Drug administration routes include oral, injectable, intravenous, intramuscular, and transfusion-based methods. The main end users are hospitals, specialty clinics, and homecare providers.
The hypoprothrombinemia treatment market research report is one of a series of new reports that provides hypoprothrombinemia treatment market statistics, including the hypoprothrombinemia treatment industry global market size, regional shares, competitors with the hypoprothrombinemia treatment market share, detailed hypoprothrombinemia treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the hypoprothrombinemia treatment industry. This hypoprothrombinemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The hypoprothrombinemia treatment market consists of revenues earned by entities by providing services such as diagnostic testing, hospital care, specialized transfusion services, therapeutic drug monitoring, and patient management programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypoprothrombinemia treatment market also includes sales of plasma-derived concentrates, synthetic clotting factors, oral anticoagulant reversal agents, blood products, and plasma derivatives. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Hypoprothrombinemia Treatment Market Characteristics3. Hypoprothrombinemia Treatment Market Trends And Strategies4. Hypoprothrombinemia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Hypoprothrombinemia Treatment Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Hypoprothrombinemia Treatment Market34. Recent Developments In The Hypoprothrombinemia Treatment Market
5. Global Hypoprothrombinemia Treatment Growth Analysis And Strategic Analysis Framework
6. Hypoprothrombinemia Treatment Market Segmentation
7. Hypoprothrombinemia Treatment Market Regional And Country Analysis
8. Asia-Pacific Hypoprothrombinemia Treatment Market
9. China Hypoprothrombinemia Treatment Market
10. India Hypoprothrombinemia Treatment Market
11. Japan Hypoprothrombinemia Treatment Market
12. Australia Hypoprothrombinemia Treatment Market
13. Indonesia Hypoprothrombinemia Treatment Market
14. South Korea Hypoprothrombinemia Treatment Market
15. Western Europe Hypoprothrombinemia Treatment Market
16. UK Hypoprothrombinemia Treatment Market
17. Germany Hypoprothrombinemia Treatment Market
18. France Hypoprothrombinemia Treatment Market
19. Italy Hypoprothrombinemia Treatment Market
20. Spain Hypoprothrombinemia Treatment Market
21. Eastern Europe Hypoprothrombinemia Treatment Market
22. Russia Hypoprothrombinemia Treatment Market
23. North America Hypoprothrombinemia Treatment Market
24. USA Hypoprothrombinemia Treatment Market
25. Canada Hypoprothrombinemia Treatment Market
26. South America Hypoprothrombinemia Treatment Market
27. Brazil Hypoprothrombinemia Treatment Market
28. Middle East Hypoprothrombinemia Treatment Market
29. Africa Hypoprothrombinemia Treatment Market
30. Hypoprothrombinemia Treatment Market Competitive Landscape And Company Profiles
31. Hypoprothrombinemia Treatment Market Other Major And Innovative Companies
35. Hypoprothrombinemia Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Hypoprothrombinemia Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on hypoprothrombinemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hypoprothrombinemia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hypoprothrombinemia treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Type I Deficiency Treatment; Type II Deficiency Treatment2) By Drug Type: Vitamin K; Fresh Frozen Plasma; Prothrombin Complex Concentrates; Recombinant Prothrombin
3) By Indication Based: Vitamin K Deficiency; Liver Diseases; Cirrhosis; Hepatitis; Anticoagulant related Hypoprothrombinemia; Genetic Disorders; Malabsorption Syndromes
4) By Drug Delivery Method: Oral Delivery; Injectable Delivery; Intravenous; Intramuscular; Transfusion Based Delivery
5) By End User: Hospitals; Speciality Clinics; Homecare Settings
Subsegment:
1) By Type I Deficiency Treatment: Prothrombin Complex Concentrates (PCCs); Fresh Frozen Plasma (FFP); Recombinant Prothrombin; Plasma-derived Coagulation Factors2) By Type II Deficiency Treatment: Vitamin K Therapy; Warfarin Reversal Agents; Liver Function Supportive Therapy; Anticoagulant Adjustment Therapies
Key Companies Profiled: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc; Sanofi S.A.; AstraZeneca
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- F. Hoffmann-La Roche AG
- Merck & Co. Inc
- Sanofi S.A.
- AstraZeneca
- Abbott
- GlaxoSmithKline
- Takeda Pharmaceuticals
- Novo Nordisk A/S
- Teva Pharmaceuticals
- CSL Limited
- Baxter International Inc.
- Fresenius Kabi AG
- Grifols S.A.
- Sun Pharmaceutical Industries Ltd.
- Octapharma AG
- Dr. Reddy's Laboratories
- Pharmascience Inc.
- Amphastar Pharmaceuticals Inc.
- Pharma Cure Laboratories